🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

20 recruiting trials

for Relapsed and/or Refractory Multiple Myeloma (RRMM)

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) NCT05519085Phase 3266 sites📍 Los Alamitos📍 San Diego📍 West Hollywood Celgene · Tests: mezigdomide, Pomalidomide, Bortezomib, Dexamethasone A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma NCT07681596Phase 1, Phase 212 sites📍 Duarte📍 Denver📍 Tampa AstraZeneca · Tests: AZD4045, Daratumumab, Aldesleukin A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma NCT07579234Phase 31 site📍 Tianjing Shandong New Time Pharmaceutical Co., LTD · Tests: F182112 single-agent, Pomalidomide + Bortezomib + Dexamethasone (PVd) or Selinexor + Bortezomib + Dexamethasone (SVd) In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma NCT07715630Phase 11 site📍 Kunming Chongqing Precision Biotech Co., Ltd · Tests: Invivo CAR-T Isatuximab in Combination With Novel Agents in RRMM - Master Protocol NCT04643002Phase 1, Phase 225 sites📍 Atlanta📍 Chicago📍 Ann Arbor Sanofi · Tests: Isatuximab, Dexamethasone, Pomalidomide, Belantamab mafodotin, Pegenzileukin Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration NCT07003568Phase 11 site📍 Shanghai Beijing GoBroad Hospital · Tests: Dual-targeting BCMA-GPRC5D CAR-T cell infusion A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma NCT07637578Phase 26 sites📍 Denver📍 Denver📍 Columbia SCRI Development Innovations, LLC · Tests: Elranatamab, Tocilizumab A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) NCT07222761Phase 344 sites📍 Atlanta📍 New York📍 Columbus Regeneron Pharmaceuticals · Tests: Linvoseltamab, Carfilzomib, Daratumumab, Dexamethasone, Pomalidomide Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma NCT06961669NA1 site📍 Hefei Anhui Provincial Hospital · Tests: Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma NCT06297226Phase 252 sites📍 Birmingham📍 Gilbert📍 Little Rock Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Tests: Arlocabtagene Autoleucel A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia NCT05759793Phase 11 site📍 Shanghai Nanjing IASO Biotechnology Co., Ltd. · Tests: CAR-GPRC5D A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma NCT07116616Phase 1, Phase 210 sites📍 Birmingham📍 San Francisco📍 Atlanta ModernaTX, Inc. · Tests: mRNA-2808 Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration NCT07003555Phase 11 site📍 Shanghai Beijing GoBroad Hospital · Tests: Dual-targeting BCMA-CD19 CAR-T cell infusion SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma NCT06622005Phase 11 site📍 Buffalo Roswell Park Cancer Institute · Tests: Cxcr1/2 Inhibitor SX-682, Daratumumab and Recombinant Human Hyaluronidase, Carfilzomib, Dexamethasone, Biospecimen Coll… Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma NCT06645678Phase 1, Phase 27 sites📍 Singapore📍 Singapore📍 Hwasun YOUNGIL KOH · Tests: Elranatamab, Mezigdomide, Dexamethasone Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma NCT05972135Phase 217 sites📍 Tucson📍 Denver📍 Denver SCRI Development Innovations, LLC · Tests: Teclistamab, Talquetamab, Tocilizumab, Oral Dexamethasone A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) NCT06615479Phase 3141 sites📍 Birmingham📍 Los Angeles📍 Orange Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Tests: BMS-986393, Cyclophosphamide, Fludarabine, Daratumumab, Pomalidomide Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma NCT06484829Phase 1, Phase 21 site📍 Chengdu Chengdu Zenitar Biomedical Technology Co., Ltd · Tests: Purinostat Mesylate 4 mg/m2, Purinostat Mesylate 6 mg/m2, Purinostat Mesylate 8.4 mg/m2 18F-Fluciclovine PET/CT in Multiple Myeloma NCT06103838Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: 18F-fluciclovine injection, 18F-FDG PET/CT A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) NCT06644118Phase 13 sites📍 Beijing📍 Xi’an📍 Hangzhou Zhejiang University · Tests: OL-101 infusion
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy